Standard BioTools Inc.

Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution

Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022

Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion

Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results

Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors

Fluidigm Corporation: Investment Opportunity

Casdin Capital, Viking Global Investors Inject $250M In Fluidigm

Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.

Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations

Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company's Biomark Platform Detects Omicron Variant of COVID-19

Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Hot Penny Stocks To Buy Now? 4 To Add To Your List Today

Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost

Fluidigm Q3 Sales Trail Estimates; Cuts Annual Guidance As COVID-19 Sales Retreat

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2021 Results - Earnings Call Transcript

Fluidigm Announces Third Quarter 2021 Financial Results